HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the... HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to trea pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
Disclosures of HUTCHMED (China)
Explore HUTCHMED (China)'s complete collection of publicly available corporate disclosures, including annual
reports, sustainability reports, financial statements, ESG data spreadsheets, and related web
publications. Each document is sourced directly from HUTCHMED (China)'s official channels and fully
traceable to its official company sources.
The table below lists all of HUTCHMED (China)'s' corporate disclosure by name and reporting period, ensuring
full transparency and easy access.
If you want to search across HUTCHMED (China)'s' disclosures for specific data or insights, use our Disclosure Search.
Name
Reporting Period
Sustainability Report
2024
Annual Report
2024
Sustainability Report
2023
Annual Report
2023
ESG Data Spreadsheet
2023
20-F
2022
Sustainability Report
2022
20-F
2021
Sustainability Report
2021
20-F
2020
Sustainability Report
2020
Real-Time Disclosures Datafeed
Get Notified Within Seconds of New Corporate Disclosures
Tracenable is building a high-speed disclosure monitoring system that delivers instant alerts when companies
publish new reports or data. Could a real-time datafeed (via SFTP, RSS or API) enhance your investment or
analytical workflows?